Alumis (ALMS) stock plummeted 56% after Phase 2b lupus trial failure. IFNGS-high subgroup showed promise. Psoriasis NDA filing still planned for Q4 2026. The post Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment appeared first on Blockonomi.